Nutex Health Posts Restated Q1 2025 Results with $21.2 Million Net Income
Reuters
Nov 19, 2025
Nutex Health Posts Restated Q1 2025 Results with $21.2 Million Net Income
Nutex Health Inc. has announced restated financial results for the first quarter ended March 31, 2025. The restated report shows total revenue of $211.8 million for Q1 2025, a 214% increase from $67.5 million in Q1 2024. Net income attributable to Nutex Health Inc. was $21.2 million, compared to a net loss of $0.4 million in the same period last year. Diluted income per share was $3.33, up from a loss per share of $0.08 in Q1 2024. The company reported EBITDA of $51.5 million and adjusted EBITDA of $72.8 million for the quarter. Nutex Health attributed improved financial performance in part to increased payments from insurance companies following successful arbitration efforts through the Independent Dispute Resolution process. For more details, the company referred investors to its amended quarterly report filed with the SEC.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutex Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-052952), on November 18, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.